Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours

British Journal of Cancer

Volumn 104, Issue 7, 2011, Pages 1067-1070

  Medley, L ^a   Morel, A N ^a   Farrugia, D ^b   Reed, N ^c   Hayward, N ^a   Davies, J M ^a   Kirichek, O ^a   Thakker, R V ^d   Talbot, D C ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

^c BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

5 fluorouracil; capecitabine; neuroendocrine tumour

Indexed keywords

CAPECITABINE; FLUOROURACIL;

ADULT; AGED; ANOREXIA; ARTICLE; BLEEDING; CANCER GROWTH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COUGHING; DIARRHEA; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLUSHING; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; HYPOKALEMIA; HYPONATREMIA; INFECTION; LEUKOCYTE COUNT; LEUKOPENIA; LIVER FUNCTION TEST; MALE; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE TUMOR; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STOMATITIS; THROMBOCYTE; TREATMENT RESPONSE;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS;

EID: 79953224421     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.76     Document Type: Article

References (19)

1. Andreyev HJ, Scott-Mackie P, Cunningham D, Nicolson V, Norman AR, Badve SS, Iveson A, Nicolson MC (1995) Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors. J Clin Oncol 13(6): 1486-1492
2. Aschele C, Sobrero A, Faderan MA, Bertino JR (1992) Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 52(7): 1855-1864
3. Basu B, Sirohi B, Corrie P (2010) Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin. Endocr Relat Cancer 17(1): R75-R90
4. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Pérez-Manga G, Rosso R, Rougier P, Schilsky RL, Capecitabine Colorectal Cancer Study Group (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13(4): 566-575 (Pubitemid 34461140)
5. Ceppi P, Volante M, Ferrero A, Righi L, Rapa I, Rosas R, Berruti A, Dogliotti L, Scagliotti GV, Papotti M (2008) Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 14(4): 1059-1064 (Pubitemid 351302551)
6. Clark OH, Benson III AB, Berlin JD, Choti MA, Doherty GM, Engstrom PF, Gibbs JF, Heslin MJ, Kessinger A, Kulke MH, Kvols L, Salem R, Saltz L, Shah MH, Shibata S, Strosberg JR, Yao JC, NCCN Neuroendo-crine Tumors Panel Members (2009) NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J Natl Compr Canc Netw 7(7): 712-747
7. Das P, Lin EH, Bhatia S, Skibber JM, Rodriguez-Bigas MA, Feig BW, Hoff PM, Eng C, Wolff RA, Krishnan S, Janjan NA, Crane CH (2005) Neoadjuvant chemoradiation with capecitabine versus infusional 5-fluorouracil (5-FU) for locally advanced rectal cancer: a matched pair analysis. Int J Radiat Oncol Biol Phys 63(Supplement 1): S164-S
8. Meta-analysis Group in Cancer (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 16(1): 301-308
9. Gehan EA (1961) The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13: 346-353
10. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19(8): 2282-2292 (Pubitemid 32366981)
11. Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, Ishitsuka H (1998) Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55(7): 1091-1097 (Pubitemid 28167730)
12. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A (2008) Gastroentero-pancreatic neuroendocrine tumours. Lancet Oncol 9(1): 61-72
13. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326(8): 519-523
14. Oberg K, Jelic S (2009) Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4): 150-153
15. Plockinger U (2007) Diagnosis and treatment of gastric neuroendocrine tumours. Wien Klin Wochenschr 119(19-20): 570-572 (Pubitemid 350060660)
16. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R, PROMID Study Group (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27(28): 4656-4663
17. Saif MW, Hashmi S, Zelterman D, Almhanna K, Kim R (2008) Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review. Int J Colorectal Dis 23(2): 139-145 (Pubitemid 350302509)
18. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P, Xeloda Colorectal Cancer Study Group (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19(21): 4097-4106 (Pubitemid 33049527)
19. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB (2008) One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendo-crine tumors in 35,825 cases in the United States. J Clin Oncol 26(18): 3063-3072